NCT01400828View on ClinicalTrials.gov

Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

May 31, 2014

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Bilastine

20 mg (encapsulated) tablets QD/14 days

DRUG

Desloratadine

5 mg (encapsulated) tablets QD/14 days

DRUG

Placebo

(encapsulated) Tablets QD/14 days

Trial Locations (1)

Unknown

Yonsei University college of Medicine, Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT01400828 - Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter